These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 35005121)
1. The role of distinct co-mutation patterns with Wang S; Jiang M; Yang Z; Huang X; Li N Genes Dis; 2022 Jan; 9(1):245-251. PubMed ID: 35005121 [No Abstract] [Full Text] [Related]
2. Clinical outcomes and immune phenotypes associated with Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711 [TBL] [Abstract][Full Text] [Related]
3. The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer. Liu L; Li F; Zhao J; Zhuo X; Lai J; Wang J; Jiang F; Xu W; Luan F; Lin X; Yang S; Fu G J Cancer; 2023; 14(6):952-965. PubMed ID: 37151388 [No Abstract] [Full Text] [Related]
4. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC). Choi DH; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Lee SH Transl Lung Cancer Res; 2023 Dec; 12(12):2448-2459. PubMed ID: 38205202 [TBL] [Abstract][Full Text] [Related]
6. KRAS Frost N; Kollmeier J; Vollbrecht C; Grah C; Matthes B; Pultermann D; von Laffert M; Lüders H; Olive E; Raspe M; Mairinger T; Ochsenreither S; Blum T; Hummel M; Suttorp N; Witzenrath M; Grohé C Transl Lung Cancer Res; 2021 Feb; 10(2):737-752. PubMed ID: 33718018 [TBL] [Abstract][Full Text] [Related]
7. Association of TP53 Mutation Status and Sex with Clinical Outcome in NSCLC Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study. Choi S; Kim SH; Lee S; Seo J; Kang M; Jung EH; Kim SA; Suh KJ; Lee JY; Kim JW; Kim JW; Lee JO; Kim YJ; Lee KW; Kim JH; Bang SM; Lee JS Cancer Res Treat; 2024 Aug; ():. PubMed ID: 39118525 [TBL] [Abstract][Full Text] [Related]
8. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553 [TBL] [Abstract][Full Text] [Related]
9. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096 [TBL] [Abstract][Full Text] [Related]
10. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Roeper J; Falk M; Chalaris-Rißmann A; Lueers AC; Ramdani H; Wedeken K; Stropiep U; Diehl L; Tiemann M; Heukamp LC; Otto-Sobotka F; Griesinger F Oncotarget; 2020 Jan; 11(3):250-264. PubMed ID: 32076486 [TBL] [Abstract][Full Text] [Related]
11. Primary Resistance to Immune Checkpoint Blockade in an Kwack WG; Shin SY; Lee SH Onco Targets Ther; 2020; 13():8901-8905. PubMed ID: 32982282 [TBL] [Abstract][Full Text] [Related]
12. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623 [TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393 [TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
16. Correlation of Albitar M; Sudarsanam S; Ma W; Jiang S; Chen W; Funari V; Blocker F; Agersborg S Oncotarget; 2018 Mar; 9(17):13682-13693. PubMed ID: 29568386 [TBL] [Abstract][Full Text] [Related]
17. Potential Predictive Value of Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262 [No Abstract] [Full Text] [Related]
18. The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer. Bai B; An X; Qu Q; Liu X; Liu Y; Wei L Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38872053 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a An J; Yan M; Yu N; Chennamadhavuni A; Furqan M; Mott SL; Loeffler BT; Kruser T; Sita TL; Feldman L; Nguyen R; Pasquinelli M; Hanna NH; Abu Hejleh T Transl Lung Cancer Res; 2021 Aug; 10(8):3608-3615. PubMed ID: 34584860 [TBL] [Abstract][Full Text] [Related]
20. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405 [No Abstract] [Full Text] [Related] [Next] [New Search]